ArticleThe American journal of case reports2025
Multiple Myeloma Presenting as Breast Metastasis: Diagnostic Challenges and Case Analysis.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bilateral breast plasmacytomas in a male patient with relapsed multiple myeloma: A case report.Radiology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Extramedullary disease represents an aggressive form of multiple myeloma (MM), with breast secondary involvement being very rare. This localization makes differential diagnosis from primary breast cancer difficult, as clinical and radiological patterns are similar between these entities. CASE REPORT An 83-year-old patient, treated for immunoglobulin A (IgA) kappa, (1q21+) MM, diagnosed in April 2016, presented to the Emergency Department for a fall. Clinically, she presented with multiple, bilateral breast lesions, confirmed by mammography and magnetic resonance imaging (MRI). Histology analysis documented a tumor with a solid and discreetly trabecular architecture, without calcifications or ductal/lobular in situ lesions, nor peritumoral lymphatic or vascular invasion. The tumor cells were negative for hormonal receptors and human epidermal growth factor receptor 2 (HER2). This histological pattern was first mistaken for an aggressive, infiltrating, pleomorphic lobular primary breast carcinoma. However, because of the history of a concomitant MM and the discordance between the histological diagnosis showing a tumor with a triple negative phenotype and the immunohistochemical profile of the pleomorphic lobular breast cancer, which usually overexpresses hormonal receptors, a histological revision was undertaken, and this confirmed the diagnosis of a breast localization of MM as the tumor cells expressed IgA kappa and multiple myeloma oncogene 1 (MUM1), and were negative for AE1/AE3 cytokeratin. The patient started fifth-line chemotherapy, but her clinical condition quickly worsened, leading to her death in June 2023. CONCLUSIONS The particularity of this case relies on the rarity of extramedullary disease from MM. Its difficult diagnosis represents a clinical challenge, as does the complexity of its management, due to a lack of evidence-based medical data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.